Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru
- 1 June 2002
- journal article
- Published by Elsevier in The Lancet
- Vol. 359 (9322), 1980-1989
- https://doi.org/10.1016/s0140-6736(02)08830-x
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Responding to Market Failures in Tuberculosis ControlScience, 2001
- The Treatment of Multidrug-Resistant Tuberculosis in TurkeyNew England Journal of Medicine, 2001
- Global Trends in Resistance to Antituberculosis DrugsNew England Journal of Medicine, 2001
- Resource implications of patients with multidrug resistant tuberculosisThorax, 2000
- Standard Short-Course Chemotherapy for Drug-Resistant TuberculosisJAMA, 2000
- Multidrug-Resistant Tuberculosis: Long Term Follow-Up of 40 Non-HIV-Infected PatientsCanadian Respiratory Journal, 2000
- Global Surveillance for Antituberculosis-Drug Resistance, 1994–1997New England Journal of Medicine, 1998
- Epidemiology, Control and Treatment of Multidrug-Resistant TuberculosisDrugs, 1996
- Multidrug-Resistant Tuberculosis in Patients without HIV InfectionNew England Journal of Medicine, 1995
- Treatment of 171 Patients with Pulmonary Tuberculosis Resistant to Isoniazid and RifampinNew England Journal of Medicine, 1993